Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses

This article first appeared on GuruFocus.

R&D Expenses: $15.7 million in Q1 2026, up from $9.4 million in Q1 2025. Non-GAAP R&D Expenses: $13.8 million in Q1 2026, compared to $7.4 million in Q1 2025. SG&A Expenses: $17 million in Q1 2026, up from $6.1 million in Q1 2025. Non-GAAP SG&A Expenses: $5.7 million in Q1 2026, compared to $1.5 million in Q1 2025. GAAP Net Loss: $26.9 million in Q1 2026, compared to $14.3 million in Q1 2025. Non-GAAP Net Loss: $13.7 million in Q1 2026, compared to $7.6 million in Q1 2025. Cash and Cash Equivalents: $799 million at the end of Q1 2026.

Warning! GuruFocus has detected 3 Warning Signs with BLTE. Is BLTE fairly valued? Test your thesis with our free DCF calculator.

Release Date: May 20, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Belite Bio Inc (NASDAQ:BLTE) has initiated the NDA rolling submission to the FDA for STARGUS disease and is on track to complete it by the second quarter of 2026. The company has completed enrollment in its Phase II/III DRAGON 2 clinical trial, which is a registration-enabling study for approval in Japan. Belite Bio Inc (NASDAQ:BLTE) has a strong cash position with $799 million in cash equivalents and U.S. Treasury bills, providing ample capital to execute its goals. The company is actively building its commercial infrastructure and has hired all commercial leadership positions in preparation for the launch. Belite Bio Inc (NASDAQ:BLTE) is engaging with the retinal community to raise awareness of SARA disease and is focused on preparing for a strong commercial launch.

Negative Points

R&D expenses increased significantly to $15.7 million in Q1 2026 from $9.4 million in Q1 2025, driven by higher spending on clinical trials and manufacturing. SG&A expenses also rose to $17 million in Q1 2026 from $6.1 million in Q1 2025, primarily due to increased share-based compensation and team expansion. The GAAP net loss for the quarter was $26.9 million, compared to $14.3 million in the same period last year. There is uncertainty regarding the FDA's requirement for DRAGON 2 study results for U.S. approval, which could impact timelines. The company is still in the process of determining the pricing strategy for its drug, with potential pricing bands ranging from $350,000 to $500,000, but no final decision has been made.

Q & A Highlights

Q: On Dragon 2, what confidence do you have based on communication with FDA that readout will not be necessary for an approval decision in the U.S.? A: Yu-Hsin Lin, CEO: We had several meetings with the FDA, and they recommended completing the DRAGON2 study with a possible path to one single study approval based on the robustness of our data. We don't believe DRAGON2 data would be applicable to our FDA filings, but it could serve as confirmatory evidence if needed.

Story Continues

Q: What are your latest thoughts on building out the commercial infrastructure, given the concentrated patient population? A: Hao-Yuan Chuang, CFO: We plan to have two teams: one for diagnostic promotion to raise disease awareness and another focused on promoting the drug. We expect to have 30 to 40 team members. We are conducting surveys and will provide a market update in September.

Q: Can you discuss the geographic atrophy (GA) interim analysis and potential scenarios if the data is strong? A: Yu-Hsin Lin, CEO: We aim for the GA interim analysis around the end of the year. If the data is strong, it would be a positive development, but we haven't strategized beyond that yet. The data will guide our decisions.

Q: What is the timeline for Japan approval for Stargardt disease? A: Yu-Hsin Lin, CEO: With the Sagigake designation, the PMDA aims for approval within three months of FDA approval, and we are on track for that timeline.

Q: How are you approaching the ex-U.S. market, particularly in Europe, regarding filing and launch strategy? A: Yu-Hsin Lin, CEO: We are focusing on FDA approval first. The FDA filing will form the basis for submissions in other jurisdictions. The timeline for ex-U.S. filings will depend on FDA responses.

Q: Have you conducted any market research with payers regarding potential pricing for Tinlaravans? A: Hao-Yuan Chuang, CFO: We have conducted several pricing projects, and payers have been supportive of the price range we are considering. While it's too early to set a price, we are looking at a reference range of $350,000 to $500,000.

Q: Assuming FDA approval in early 2027, how quickly can you launch the drug, and what is the expected patient uptake? A: Hao-Yuan Chuang, CFO: Manufacturing is straightforward, so we expect a quick launch post-approval. We are preparing the supply chain and will provide more detailed patient uptake estimates in September.

Q: Should we expect operating expenses to continue increasing as you approach the FDA decision? A: Hao-Yuan Chuang, CFO: Yes, expenses will likely increase due to team expansion and commercialization activities. However, we have a strong cash position with $799 million, which comfortably supports our launch and pipeline development.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

View Comments